2013
Almanac 2013: Novel non-coronary cardiac interventions
Meier P, Franzen O, Lansky AJ. Almanac 2013: Novel non-coronary cardiac interventions. Heart 2013, 99: 1309. PMID: 23899781, DOI: 10.1136/heartjnl-2013-304430.Peer-Reviewed Original ResearchMeSH KeywordsAortic Valve StenosisAtrial AppendageAtrial FibrillationCardiologyDenervationEmbolic Protection DevicesEquipment DesignHeart DiseasesHeart Valve DiseasesHeart Valve Prosthesis ImplantationHumansKidneyMitral Valve InsufficiencyPercutaneous Coronary InterventionSeptal Occluder DeviceTreatment OutcomeConceptsHigh riskPercutaneous left atrial appendage closureImportant new treatment optionInterventional cardiologyLeft atrial appendage closureNon-pharmacologic therapiesAtrial appendage closureAortic valve stenosisCoronary artery diseaseAortic valve diseaseSurgical valve repairNew treatment optionsImportant clinical evidenceRecent clinical dataRenal denervationResistant hypertensionStroke preventionAppendage closureElderly patientsArtery diseasePercutaneous treatmentValve stenosisValvular diseaseValve diseaseClinical evidence
2009
Prognostic Impact of Blood Transfusion After Primary Angioplasty for Acute Myocardial Infarction Analysis From the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial
Nikolsky E, Mehran R, Sadeghi HM, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Stone GW. Prognostic Impact of Blood Transfusion After Primary Angioplasty for Acute Myocardial Infarction Analysis From the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial. JACC Cardiovascular Interventions 2009, 2: 624-632. PMID: 19628185, DOI: 10.1016/j.jcin.2009.05.004.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAge FactorsAgedAnemiaAngioplasty, Balloon, CoronaryAntibodies, MonoclonalErythrocyte TransfusionFemaleHeart DiseasesHumansImmunoglobulin Fab FragmentsKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionOdds RatioPlatelet Aggregation InhibitorsProportional Hazards ModelsProspective StudiesRadiographyRecurrenceRisk AssessmentRisk FactorsSeverity of Illness IndexSex FactorsStrokeTime FactorsTreatment OutcomeConceptsPrimary percutaneous coronary interventionAcute myocardial infarctionPrimary PCIRBC transfusionCADILLAC trialClinical outcomesComposite major adverse cardiac eventsAcute Myocardial Infarction AnalysisMajor adverse cardiac eventsCoronary artery bypass surgeryRed blood cell transfusionMechanical reperfusion therapyAdverse cardiac eventsArtery bypass surgeryBlood cell transfusionTriple vessel diseasePercutaneous coronary interventionBaseline anemiaMajor bleedingTransfusion propensityCell transfusionIndex hospitalizationMultivariable adjustmentPrimary angioplastyReperfusion therapy
2006
Drug-Eluting Stents in the Treatment of Intermediate Lesions Pooled Analysis From Four Randomized Trials
Moses JW, Stone GW, Nikolsky E, Mintz GS, Dangas G, Grube E, Ellis SG, Lansky AJ, Weisz G, Fahy M, Na Y, Russell ME, Donohoe D, Leon MB, Mehran R. Drug-Eluting Stents in the Treatment of Intermediate Lesions Pooled Analysis From Four Randomized Trials. Journal Of The American College Of Cardiology 2006, 47: 2164-2171. PMID: 16750680, DOI: 10.1016/j.jacc.2006.01.068.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsDrug-eluting stentsTarget vessel revascularizationIntermediate lesionsAngiographic restenosisMyocardial infarctionCardiac deathStent thrombosisDe novo coronary artery lesionsIntroduction of DESLate major adverse cardiac eventsEfficacy of DESNovo coronary artery lesionsBinary angiographic restenosisAdverse cardiac eventsCoronary artery lesionsCurrent treatment paradigmsTreatment of patientsIntermediate coronary lesionsBalloon-expandable stentsLower ratesEverolimus trialsRestenosis reductionTAXUS IVVessel revascularization
2005
Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction
Lansky AJ, Pietras C, Costa RA, Tsuchiya Y, Brodie BR, Cox DA, Aymong ED, Stuckey TD, Garcia E, Tcheng JE, Mehran R, Negoita M, Fahy M, Cristea E, Turco M, Leon MB, Grines CL, Stone GW. Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction. Circulation 2005, 111: 1611-1618. PMID: 15811868, DOI: 10.1161/01.cir.0000160362.55803.40.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionPrimary stentingAddition of abciximabBody surface areaCADILLAC trialMyocardial infarctionRisk factorsFemale genderIschemic target vessel revascularizationLower body surface areaMajor adverse cardiac eventsOverall adverse outcomesTIMI grade 3Adverse cardiac eventsTarget vessel revascularizationClinical risk factorsComorbid risk factorsInterventional treatment strategiesImportant independent determinantHigh mortality rateMACE ratePrimary angioplastyCardiac eventsSymptom onsetIndependent predictors